Evaxion A/S

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
5.780 ^USD	-6.92%		-7.96%	+36.74%

Dec. 15	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
Dec. 11	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

European Equities Traded in the US as American Depositary Receipts Climb Higher in Thursday Trading

Published on 08/08/2024 at 11:09 am EDT - Modified on 08/08/2024 at 11:11 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Evaxion A/S

Dec. 15	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
Dec. 11	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Dec. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT
Dec. 09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
Dec. 08	European Equities Traded in the US as ADRs Little Changed in Monday Trading	MT
Dec. 08	Evaxion A/S Presents New Data for EVX-04, a Cancer Vaccine Candidate for Acute Myeloid Leukemia at ASH Annual Meeting	CI
Dec. 01	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
Nov. 28	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week	MT
Nov. 26	European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading	MT
Nov. 24	European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading	MT
Nov. 21	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week	MT
Nov. 21	Evaxion A/S prospectus relates to offer and sale by selling shareholder of up to 38,450,000 ordinary shares	RE
Nov. 20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Nov. 20	Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1	RE
Nov. 20	Evaxion A/S Announces Positive Data for Lead Antigens in Cytomegalovirus Vaccine Program Evx-V1	CI
Nov. 19	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT
Nov. 13	European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading	MT
Nov. 11	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
Nov. 07	European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Down Modestly for Week	MT
Nov. 06	Evaxion A/S, Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	Evaxion A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 06	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
Nov. 06	Techbio firm Evaxion posts Q3 net income of $4.6 mln	RE
Nov. 03	Evaxion A/S Expands R&D Pipeline with New AI- Designed Precision Cancer Vaccine Candidate	CI
Oct. 31	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	MT

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jan. 11 - J.P. Morgan Healthcare Conference

More about the company